Mark Cuban’s generic-drug play isn’t just another media headline—it’s a stress test for the entire pharmaceutical value chain.
Here’s the agitation: for decades, the industry has treated “generic entry” like a predictable event—file the paperwork, wait…

Biotech hiring isn’t just about headcount. It’s often about patent strategy—and the job postings can be the earliest signal that a licensing deal is about to get real.
Here’s the agitation: most people read biotech job ads as standalone announcements—“…

Pharma’s “Patent Cliff” Isn’t a Cliff—It’s a Pricing Strategy
The market keeps calling it a cliff. But in practice, reformulation is less about science and more about monetization—an increasingly sophisticated playbook that helps drug makers keep reven…

Drug pricing transparency is having a moment—and not the kind that ends with a victory lap.
For years, policymakers and pundits have treated “transparency” as the clean, technocratic fix: publish the numbers, shine a light on the system, and the market…

Mark Cuban’s “cost-plus” pitch isn’t just a consumer-friendly headline—it’s a live test of how America’s drug pricing system will evolve under pressure.
The strategic question isn’t whether lower prices are possible. It’s whether the incentives, infras…

Pharma doesn’t “miss” patent dates. It just doesn’t miss them twice.
Behind every headline about a blockbuster’s extended protection window is a quieter, more mechanical reality: companies track IND and NDA timelines with near-military precision—becaus…

Pharma’s patent clock doesn’t tick in public. It ticks in spreadsheets, legal holds, and “watch lists” that start years before a deadline ever hits the calendar.
That’s the real story behind how companies track IND and NDA dates to win global patent ex…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Generic competition is no longer just about filing a paragraph IV. It’s about proving your product behaves like the reference—down to the biology.
That’s the real story behind the “bioequivalence playbook” for ANDA approvals—and why the companies tha…

How does fruit juice impact Lipitor absorption? The effectiveness of Lipitor (atorvastatin), a statin medication used to… https://www.Drugchatter.com/chat/24737/does-lipitor’s-effectiveness-vary-with-any-fruit-juice/